Company Overview
| Stock Name | Recbio-B |
|---|---|
| Stock Code | 02179 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家疫苗公司,擁有高價值亞單位疫苗組合,並由自主研發的技術所驅動。我們主要專注於HPV候選疫苗的研發。我們的疫苗組合有12款疫苗,包括我們的核心產品REC603,一款重組HPV九價疫苗,目前處於III期臨床試驗階段。 |
| Listing Date | 2022-03-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中国 江蘇省 泰州市 中國醫藥城 疫苗工程中心A217室 |
| Business Address (Hong Kong) | 香港 灣仔 皇后大道東248號 大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | recbio.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 24.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 12,400 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-03-21 to 2022-03-24 |
| Global Offering Shares | 30,854,500 shares |
| HK Public Offer Shares (Initial) | 3,085,500 shares (10.0%) |
| Public Offer Lots (Initial) | 6,171lots (Pool A3,085lots,Pool B3,086lots) |
| International Placing Shares (Initial) | 27,769,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 479,104,500 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 54.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 765,191,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 12,400 |
| 2 lots | 1,000 | HK$ 24,800 |
| 3 lots | 1,500 | HK$ 37,200 |
| 4 lots | 2,000 | HK$ 49,600 |
| 5 lots | 2,500 | HK$ 62,000 |
| 6 lots | 3,000 | HK$ 74,400 |
| 7 lots | 3,500 | HK$ 86,800 |
| 8 lots | 4,000 | HK$ 99,200 |
| 9 lots | 4,500 | HK$ 111,600 |
| 10 lots | 5,000 | HK$ 124,000 |
| 12 lots | 6,000 | HK$ 148,800 |
| 14 lots | 7,000 | HK$ 173,600 |
| 16 lots | 8,000 | HK$ 198,400 |
| 18 lots | 9,000 | HK$ 223,200 |
| 20 lots | 10,000 | HK$ 248,000 |
| 30 lots | 15,000 | HK$ 372,000 |
| 40 lots | 20,000 | HK$ 496,000 |
| 50 lots | 25,000 | HK$ 620,000 |
| 60 lots | 30,000 | HK$ 744,000 |
| 70 lots | 35,000 | HK$ 868,000 |
| 80 lots | 40,000 | HK$ 992,000 |
| 90 lots | 45,000 | HK$ 1,116,000 |
| 100 lots | 50,000 | HK$ 1,240,000 |
| 120 lots | 60,000 | HK$ 1,488,000 |
| 140 lots | 70,000 | HK$ 1,736,000 |
| 160 lots | 80,000 | HK$ 1,984,000 |
| 180 lots | 90,000 | HK$ 2,232,000 |
| 200 lots | 100,000 | HK$ 2,480,000 |
| 400 lots | 200,000 | HK$ 4,960,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 300,000 | HK$ 7,440,000 |
| 800 lots | 400,000 | HK$ 9,920,000 |
| 1,000 lots | 500,000 | HK$ 12,400,000 |
| 1,200 lots | 600,000 | HK$ 14,880,000 |
| 1,400 lots | 700,000 | HK$ 17,360,000 |
| 2,000 lots | 1,000,000 | HK$ 24,800,000 |
| 3,085 lots | 1,542,500 | HK$ 38,254,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.95B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +380% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 11,881,791,600 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 2,226,584,176 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币179.4百万元 |
| Period-End Cash Balance | 人民币355.8百万元 |
| Listing Expenses | ~HK$ 92,791,600 |
| Listing Expenses / Funds Raised | ~12.13% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 |
|---|---|---|
| Other income and gains, net | 9,551 | 27,810 |
| Administrative expenses | -18,416 | -143,045 |
| Net finance costs | -37,112 | -56,308 |
| Profit before tax | -179,400 | -657,566 |
| Income tax expense | 0 | 0 |
| Profit for the year | -179,400 | -657,566 |
| Profit attributable to owners | -179,400 | -657,561 |
Balance Sheet
| Item | 2020 | 2021 |
|---|---|---|
| Cash and cash equivalents | 355,821 | 1,182,562 |
| Inventories | 7,762 | 23,549 |
| Total current assets | 709,376 | 1,294,571 |
| Total current liabilities | 57,481 | 139,293 |
| Total equity | -1,008,784 | 1,673,296 |
| Interest-bearing borrowings | 0 | 50,000 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-09 |
|---|---|---|---|
| Net cash from operating activities | -138,639 | -70,336 | |
| Net cash from investing activities | -345,639 | -258,587 | |
| Net cash from financing activities | 490,171 | 680,385 | |
| Depreciation of PP&E | 1,452 | 6,556 | 10,394 |
| Depreciation of right-of-use assets | 2,874 | 6,207 | 5,621 |
| Purchase of PP&E | -78,966 | -138,288 | -195,773 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 25.25 |
|---|---|
| First Day Open | HK$ 25.0 |
| First Day Change | 1.81% |
| First Day Volume | 3440000.0 |
| First Day Turnover | 86207200.0 |
| Use of Proceeds | 1、約47.3%或317.9百萬港元將分配予繼續優化、開發及商業化我們的HPV疫苗管線;
2、約17.7%或119.3百萬港元將用于我們新冠肺炎疫苗(即ReCOV)的臨床前及臨床研究、注冊;
3、約21.1%或142.0百萬港元將用于其他候選疫苗的臨床前及臨床研究、注冊;
4、約6.7%或44.7百萬港元將用于進一步加強我們的研發能力及提高營運效率;5、約7.2%或48.5百萬港元將用作我們的營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (8)
Joint Lead Managers (9)
Morgan Stanley Asia Limited CE AAD291
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956
海通国际证券有限公司 CE AAF806
广发证券(香港)经纪有限公司 CE AOB364
SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
VALUABLE CAPITAL LIMITED CE AUL711
Livermore Holdings Limited CE BJN764
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 78,231,600 HKD | — | 10.22% | — | 6 months | 2022-09-30 |
| 2 | SCC Growth VI Holdco C (HK) Limited | 7,812,000 HKD | — | 1.02% | — | 6 months | 2022-09-30 |
| 3 | SCHP Master Fund | 15,636,400 HKD | — | 2.04% | — | 6 months | 2022-09-30 |
| 4 | 扬子江(香港)有限公司 | 312,938,800 HKD | — | 40.90% | — | 6 months | 2022-09-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉勇 | — |
| Company Secretary | 陳青青、劉准羽 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 劉博士透過泰州元工等受控法團持有約20.18%權益,為最大股東。 |
|---|




